Charting a proven path in neuropsychiatry
Charting a proven path in neuropsychiatry
Description
Puretech Ownership1
Stage of Development
Charting a proven path in neuropsychiatry
36.7% Equity
Phase 2
Description
Charting a proven path in neuropsychiatry
Puretech Ownership1
36.7% Equity
Stage of Development
Phase 2
1 As of October 18, 2024, PureTech’s percentage ownership of Seaport Therapeutics was approximately 36.7% on a partially diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans. PureTech ownership reflects current ownership and does not take into account any potential future dilution, if applicable, as a result of conversion of that debt amount.

Charting a proven path in neuropsychiatry

Seaport is advancing a clinical-stage pipeline of neuropsychiatric medicines that includes its most advanced therapeutic candidate, SPT-300 (formerly known as LYT-300), an oral prodrug of allopregnanolone, which is being advanced for the treatment of major depressive disorder with or without anxious distress, SPT-320 (formerly known as LYT-320), a novel prodrug of agomelatine, which is being advanced for the treatment of Generalized Anxiety Disorder (GAD), and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen, which is in development for the treatment of mood and other neuropsychiatric disorders.
  • Program Discovery Process by the PureTech Team
    • With intersecting interests in enabling promising neuropsychiatric drugs to reach their full potential and the emerging science around the lymphatic system, we identified a breakthrough technology being developed at Monash University that had the potential to selectively transport therapeutic molecules through the lymphatic system.
    • With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph technology has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including hepatotoxicity. We prioritized areas of high unmet patient need where the broad application of treatment options with validated efficacy was untapped due to these issues. The Glyph platform has been refined at PureTech and Seaport to efficiently generate multiple therapeutic candidates within Seaport’s pipeline.
  • Milestones Achieved & Developmental Status
  • Expected Milestones
  • Intellectual Property
Seaport Therapeutics is advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. All the therapeutic candidates in the pipeline of first and best-in-class medicines are based on the Glyph platorm, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects. 

Press Releases